ORION CORPORATION STOCK EXCHANGE RELEASE 20 DECEMBER 2012 at 11:22 EET
Orion Corporation ("Orion") and Mylan Pharmaceuticals Inc. ("Mylan") have
executed a settlement agreement on lawsuit filed by Orion in the United States
against Mylan regarding Mylan's submission of abbreviated new drug application
("ANDA") for generic version of Orion's Comtan® product (strength 200 mg).
Comtan is used as an adjunct to levodopa/carbidopa therapy to treat patients
with idiopathic Parkinson's Disease who experience the signs and symptoms of
end-of-dose "wearing-off". Comtan contains entacapone, a COMT enzyme inhibiting
agent originated and patented by Orion.
The lawsuit was filed by Orion in the U.S. in 2011. Under the terms of the
settlement agreement, Mylan may launch generic version of Comtan 200 mg on 1
April 2013 at the earliest.
Subject to the Court's approval, the case will be dismissed and the U.S. Patent
No. 5,446,194 remains in force.
In compliance with the applicable U.S. laws, Orion will file the above agreement
with the United States Federal Trade Commission and the United States Department
of Justice.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
[HUG#1666564]